CLAIMS

1. A pharmaceutical agent comprising an antiplatelet agent in combination with a 5-amidino-2-hydroxybenzene-sulfonamide derivative represented by the general formula:

$$H_2N$$
 SO_2NH
 OR
 SO_2CH_3

5

15

wherein R represents a hydrogen atom or a lower alkyl group; and Z represents a hydrogen atom or a hydroxy group, or a pharmaceutically acceptable salt thereof.

- 2. A pharmaceutical agent as claimed in claim 1, wherein the antiplatelet agent is a compound selected from the group consisting of aspirin, dipyridamole, cilostazol, ticlopidine and clopidogrel.
 - 3. A pharmaceutical agent as claimed in claim 1, wherein the antiplatelet agent is a compound selected from the group consisting of aspirin, dipyridamole, cilostazol and ticlopidine.
- 4. A pharmaceutical agent as claimed in claim 1, wherein the 5-amidino-2-hydroxybenzenesulfonamide derivative is a compound selected from the group consisting of n-butyl [4-[2-[2-hydroxy-5-(N-hydroxycarbamimidoyl)benzene-sulfonylamino]ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetate, [4-[2-[2-hydroxy-5-(N-hydroxy-carbamimidoyl)benzenesulfonylamino]ethyl]-2'-methane-sulfonylbiphenyl-3-yloxy]acetic acid, n-butyl [4-[2-(5-amidino-2-hydroxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetate and [4-[2-(5-amidino-2-hydroxybenzenesulfonylamino)-ethyl]-2'-methanesulfonylbiphenyl-3-yloxy]acetic acid.

- 5. A pharmaceutical agent as claimed in any one of claims 1 to 4, which is an agent for the prevention or treatment of thromboembolism.
- 6. A pharmaceutical agent as claimed in calim 5, wherein the thromboembolism is arterial thromboembolism.
 - 7. A pharmaceutical agent as claimed in claim 5, wherein the thromboembolism is venous thromboembolism.
 - 8. A pharmaceutical agent as claimed in claim 6, wherein the arterial thromboembolism is unstable angina, cardiac
- infarction, cerebral thrombosis, atherothrombotic cerebral infarction, lacunar infarction, chronic arterial occlusive disease, cardiogenic embolism, peripheral arterial occlusive or embolism attributed to coronary intervention.
- 9. A pharmaceutical agent as claimed in claim 7, wherein the venous thromboembolism is sinus thrombosis, traveler's thrombosis, pulmonary embolism or deep-vein thrombosis.